|
Panels & Speakers
|
Every year we strive
to bring outside-the-box, provocative panels that discuss issues and opportunities
relevant today. We invite entrepreneurs, investors, corporate executives
that are known for their innovative vision and successful track record
to share their past experience and expectation of things to come.
|
|
Opening
Keynote
|
|
 Dr.
Richard N. Foster
Managing Partner
Millbrook Management Group
Mr. Foster is managing
partner of Millbrook Management Group LLC. Prior to forming Millbrook
Mr. Foster was a senior partner and director of McKinsey and Company,
where his most recent position was as managing director of McKinsey's
Private Equity practice. Mr. Foster joined the Firm in 1973, was elected
partner in 1977, and senior partner in 1982. Mr. Foster has written two
best selling business books, Innovation: The Attacker's Advantage (1986)
and Creative Destruction (2001), that focus on the relationship between
innovation, capital formation and destruction, and risk. While at McKinsey,
Foster served more than 50 leading global companies primarily in the healthcare,
electronics and chemicals arena. He also devoted much of his time to the
top management of a Fortune 50 healthcare company where he was a lead
external advisor from 1990 – 2003.
|
|
Keynote
Conversation
|
|
 Ed
Penhoet, Ph.D.
Former President - Gordon & Betty Moore Foundation
Founder - Chiron
Ed Penhoet was the
Gordon & Betty Moore Foundation's president from 2004 - 2007, and
prior to that, Ed worked as the organization's chief program officer for
the Science Program.Before joining the foundation the Foundation, Ed served
as dean of the School of Public Health at the University of California,
Berkeley. In 1981, he co-founded Chiron Corporation and served as its
chief executive officer until 1998. For 10 years prior to founding Chiron,
Ed was a faculty member of the Biochemistry Department of U.C. Berkeley.
Ed currently serves as the vice chairman of the Independent Citizen’s
Oversight Committee which oversees the California Institute for Regenerative
Medicine created by the passage of Proposition 71, the stem cell initiative.
|
|
 Matthew
Bishop
Chief Business Writer
The Economist
Matthew Bishop is
Chief Business Writer/US Business Editor of The Economist, based in New
York. He was previously The Economist's London-based Business Editor,
and has also served as its New York Bureau Chief. Matthew is the author
of several Economist special survey supplements, including most recently
"The Business of Giving", which looks at the industrial revolution
taking place in philanthropy; "Kings of Capitalism", which anticipated
and analysed the recent boom in private equity; and "Capitalism and
its Troubles", an examination of the impact of problems such as the
collapse of Enron. Matthew is the author of "Essential Economics",
the official Economist layperson's guide to economics. Before joining
The Economist, Matthew was on the faculty of London Business School, where
he co-authored three books for the Oxford University Press, on subjects
ranging from privatisation and regulation to corporate mergers.
Listen
to audio recording
|
| |
| Panels
|
| |
|
Town Hall Forum:
Post Stimulus Response - Challenges and Opportunities in Funding for Life
Sciences
Presented in partnership with California
Healthcare Institute
9:35 - 10:30 AM - Gold Room
The American Recovery
and Reinvestment Act (AKA the Stimulus Package) calls for an additional
$10B in funding for NIH alone, with quick turn-around times for "solutions"
that are close to being deployed. What programs and what resources are
being put in place, and what are their parameters? Is this a brand-new
mission-oriented funding program or are these supplemental funds to augment
current priorities? How can companies position themselves to benefit from
this and similar near-term opportunities in a time of economic uncertainty?
extensive Q&A exchanges with the audience.
Listen
to audio recording
|
|
Moderator
David Gollaher, California Healthcare
Institute
Panelists:
Danielle Peters, Fabiani & Company
Conrad Clyburn, The Clymer Group,
LLC
Jeff Himawan, Essex Woodlands Health
Ventures
|
|
|
Novel Product
Development Approaches…what can we learn from them?
1:20 - 2:20 PM - Gold
Room
To control and de-risk high development costs, companies across the sector
are experimenting with novel approaches to product development. Large
pharma companies are experimenting with virtually integrated autonomous
units, or are banding together to build consortia to address core needs
in drug discovery. In some instances, at almost twice the speed and less
than a third of the cost of the standard process—reducing 12+ months
off the development time. Smaller companies in both devices and therapeutics
are turning to virtual/lean models to speed up their product development
cycles. How are these teams doing it better than the rest of us, are these
unique teams, are they lucky, do they have the luxury of access to large
amounts of capital?.... what can small emerging companies learn or emulate
to get to market faster from these models?
Listen
to audio recording
|
|
Moderator
Joanna Schulman, Thallo Biosciences
Panelists:
Roger
Stern, Ph.D., Stellartech Research; Coronis Medical Ventures
Donald Frail, Pfizer
Ed Schnipper, ProjeX Therapeutics
|
| |
| |
|
Panelists |
|
|
|
 David Gollaher
President and Chief Executive Officer
California Healthcare Institute
David Gollaher, Ph.D.
co-founded CHI in 1993. Earlier in his career, he was a senior executive
at Scripps Clinic and Research Foundation. Previously he served on the
faculties of Harvard University, University of California, San Diego,
the Graduate School of Public Health at SDSU, and the Overseas School
of Rome. He is an award-winning historian of science and medicine, the
author of three books and numerous articles in the fields of health policy,
the economics of biomedical research and development, bioethics and the
history of medicine. Gollaher completed his undergraduate studies at the
University of California and earned his master’s and Ph.D. degrees
from Harvard University. He is also a co-founder of Vision Robotics Corporation
and is named on five patents in autonomous robotic navigation. CHI represents
more than 250 leading academic research, biotechnology, medical device
and pharmaceutical organizations in California. CHI’s mission is
to advance responsible public policies that foster medical innovation
and promote scientific discovery.
|
|
 Danielle Peters
Fabiani & Company
Since 2004, Ms. Peters
has assisted Fabiani & Company clients in seeking federal funding
and partnerships for research and commercialization of novel technologies.
Ms. Peters has represented companies in the life sciences, defense technology
and green technology sectors. Ms. Peters manages client relationships
with Federal agencies and Congress and has a proven track record in successfully
positioning clients for federal funding and federal partnership opportunities.
On policy matters, Ms. Peters is engaged in issues that include patent
reform, Small Business Administration Authorization, public health preparedness
and incentives for clean energy commercialization. Federal agencies of
expertise include the Department of Health and Human Services (including
the Biomedical Advanced Research and Products Agency, National Institutes
of Health and Centers for Disease Control and Prevention), Department
of Defense, Department of Veterans Affairs, Department of Energy, National
Aeronautics and Space Agency and Department of Commerce.
Ms. Peters received
her B.A. from McGill University in Montreal, Canada and her M.A. in Commercial
Diplomacy from the Monterey Institute of International Studies in Monterey,
California. She speaks Spanish, Hebrew and French.
|
|
Joanna Schulman
Founder & Managing Partner
Thallo Biosciences
Joanna
Schulman is founder and managing partner of Thallo Bioscience Advisors,
LLC a financial and strategic advisory firm serving clients globally in
the life sciences sector. She has extensive experience working with organizations
ranging from startups to multinational enterprises providing advisory
services in the areas of corporate financing & growth strategies,
asset acquisition & divestiture, M&A, partnering and alliances,
licensing opportunities, company/product positioning and capital raising.
Prior
to establishing Thallo, Joanna worked with Deloitte to build their national/international
life sciences practice and has held various executive positions in industry
including Vice President of pharmaceutical commodities trading company
and Consulting Director to Pathways Cancer Center.
Joanna
is and active participant, committee member and speaker for industry organizations
including BIO, BayBio, Larta & CHI. She has served on the board and
steering committees for a wide range of non-profit and patient advocacy
groups.
|
|
 Roger
Stern, Ph.D.
President & CEO
Stellartech Research Corporation
Managing Director
Coronis Medical Ventures
Roger currently serves
as President and CEO of Stellartech Research Corporation. He founded the
company in 1988 to develop innovative electronic devices for start-up
companies in the medical industry. Stellartech has grown steadily over
the years, and has built a strong reputation based on its expertise in
the development and manufacture of complex energy delivery systems and
other sophisticated medical equipment. Today, Stellartechís services
also include the design and manufacture of disposable devices. The company
currently employs over 140 people in its state-of-the-art facilities.
Roger earned a BSEE
degree at Syracuse University and went on to attend graduate school at
Stanford University, receiving both a Masters and Ph.D. degree in Electrical
Engineering, with emphasis on medical imaging. During his graduate studies,
Roger held a position at the Palo Alto Medical Research Foundation, researching
innovative cardiovascular applications for ultrasound. He also spent significant
time in the Radiology Department of Stanford University Medical Center,
working with physicians and patients to collect imaging data required
for his Ph.D. thesis.
Utilizing Stellartech's
virtual company model, Roger has co-founded and incubated a number of
successful companies. In 2004, Roger was named one of Medical Device and
Diagnostic Industry's 100 Notable People.
|
|
 Donald
Frail
VP of Global Research and Development, Director of the St. Louis Laboratories
Pfizer Inc.
|
|
 Conrad
Clyburn
Co-Founder & Senior Partner
The Clymer Group
Mr. Clyburn is Co-Founder
and Senior Partner of The Clymer Group, LLC; a "Lab to Market"
internet property development and strategic advisory services firm. Prior
to founding Clymer Group, Mr. Clyburn was Associate Director, Georgetown
University, Imaging Science and Information Systems (ISIS) Center. From
1997 to 2007, in an Intergovernmental Personnel Agreement (IPA) capacity,
Mr. Clyburn served as Director, Program Integration and Planning for the
Department of Defense Telemedicine and Advanced Technology Research Center
(TATRC) . In that position, Mr. Clyburn was responsible for life cycle
management of over 500 projects supported by a medical research and development
budget that ultimately exceeded $400 million/year. The TATRC portfolio
included investments in telemedicine, eHealth, advanced prosthestics,
simulators, robotics, biomaterials and nanotechnology, and generated numerous
scientific articles, invention disclosures, patent filings, licensings
and start-up businesses. While on Active Duty, Mr. Clyburn served as Medical
Operations Advisor to the Saudi Arabian Ministry of Defense and Aviation.
He is recipient of the Food and Drug Administration, Commissioner's Special
Citation, the U.S. Army, Thurman Award of Excellence in Telemedicine and
Advanced Technology, and the U.S. Army Medical Service Corps, Award of
Excellence. Mr. Clyburn retired from the U.S. Army in 1997, and is a graduate
of Rutgers University, the University of Maryland and the Stanford University
Medical Informatics Short Course.
|
|
 Jeff
Himawan
Managing Director
Essex Woodlands Health Ventures
Jeff Himawan, PhD,
has over 20 years of experience as a scientist, entrepreneur and venture
capitalist. He began his industrial career in 1987 as a bench scientist
at Genzyme Corporation. In 1996, Dr. Himawan co-founded Seed-One Ventures,
a venture capital firm that specializes in the initial formation, financing,
and early operational development of technology-based companies. As a
Managing Director at Seed-One Ventures, he led the formation and management
of Elusys Therapeutics, a Fund IV company. He has written several patents
in the fields of wireless communication, biotechnology and protein chemistry.
Dr. Himawan first
joined Essex Woodlands in 1999 as an Adjunct Partner; he became a Partner
in 2001. He serves on the Board of Directors of Catalyst Biosciences,
Receptor BioLogix, MediciNova, Light Sciences Oncology, Ception Therapeutics,
Horizon Therapeutics and Symphogen. Dr. Himawan holds a Bachelor of Science
degree from the Massachusetts Institute of Technology and a PhD degree
in Biological Chemistry and Molecular Pharmacology from Harvard University.
|
|
Ed
Schnipper
President
ProjeX Therapeutics
Dr Schnipper is currently
President of ProjeX Therapeutics a startup company seeded by Sofinnova.
Prior to that he held the CMO and CEO positions at Novacea and Cellgate
respectively and was also VP of clinical at Alza and began his pharmaceutical
career at Hoffman LaRoche. During this time he has worked on numerous
clinical programs leading to successful IND and NDA filings across multiple
therapeutic areas. He went to Medical School at Georgetown University
and trained in hematology at NYU and oncology at Memorial Sloan Kettering
Cancer Institute and practiced oncology in both academic and private practice
for a number of years before joining the pharmaceutical industry
|
|